Clinical Outcomes of Metabolic Surgery on Diuretic Use in Patients With Heart Failure

Document Type

Article

Publication Date

7-17-2024

Publication Title

American Journal of Cardiology

Abstract

The beneficial impacts of metabolic surgery (MS) on patients with heart failure (HF) are incompletely characterized. We aimed to describe the cardiac and metabolic effects of MS in patients with HF and hypothesized that patients with HF would experience both improved metabolic and HF profiles using glycemic control and diuretic dependency as surrogate markers. In this single-center, university-affiliated academic study in the United States, a review of 2,342 hospital records of patients who underwent MS (2017 to 2023) identified 63 patients with a medical history of HF. Preoperative characteristics, 30-day outcomes, and up to 2-year biometric and metabolic outcomes, medication usage, and emergency department utilization were collected. At 24 months, mean body mass index change was −16 kg/m2 (p < 0.001) that corresponded to a mean percentage total body weight loss of 29% (p < 0.001). Weight loss was accompanied by significant reductions in hemoglobin A1c (p < 0.001) and a 65% decrease in diuretic use at 24 months after surgery (p < 0.001). Similarly, emergency visits for cardiac conditions (p = 0.06) and intravenous diuresis (p = 0.07) trended favorably at 1 year after surgery compared with 1 year before surgery but were not statistically significant. In conclusion, in patients with HF who were carefully selected, MS appears to provide significant reduction in oral diuretic dependency, and metabolic improvements with trends toward lower rates of emergency department utilization.

First Page

128

Last Page

133

PubMed ID

39029720

Volume

226

Link to Full Text

Share

COinS